home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Reversible Drug For Thromboses

  October, 26 2004 8:39
your information resource in human molecular genetics
Anticoagulant drugs, such as streptokinase and tissue plasminogen activator (tPA), are widely used to treat and prevent blood clots, but they carry a risk of causing serious hemorrhage. In the November issue of Nature Biotechnology, Bruce Sullenger and colleagues report that an unconventional drug, comprising the nucleic acid RNA, is efficacious in animals as an anticoagulant. What's more, it comes with its own antidote (an RNA complement that binds and neutralizes the drug), allowing better control of anticoagulant activity, which may be important in settings such as the surgical operating theatre where anticoagulants are often needed.

The drug and the antidote were shown to work in clinically predictive models of cardiovascular disease in both pigs and mice. In addition, the antidote prevented hemorrhage in the clipped tails of mice that had received the anticoagulant, demonstrating the efficacy of the antidote in a surgical trauma model.

Author contact:

Bruce Sullenger (Duke University Medical Center, Durham, NC, USA)
Tel: +1 919 684 6375, E-mail: b.sullenger@cgct.duke.edu

Also available online.

(C) Nature Biotechnology press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.